About the Company
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants desugned for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AGEN News
Agenus Inc. (AGEN)
As of 12:22 PM EDT. Market Open. LEXINGTON, Mass., May 01, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30 ...
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) ...
Buy Rating for Agenus Inc. on Strong Financial Position and Promising Clinical Milestones
Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Agenus (AGEN – Research Report) on May 8 and set a price target of ...
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that ...
Why MiNK Therapeutics Inc (NASDAQ:INKT) Stock up 20.42% in Last Week?
The firm’s stock price fluctuated 20.42% within the last five trades and 23.28% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the ...
Agenus: Q1 Earnings Snapshot
LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Agenus Inc. (AGEN) on Tuesday reported a loss of $63.5 million in its first quarter. The Lexington, Massachusetts-based company said it had a ...
Loading the latest forecasts...